CytoTherapeutics Inc. said Patrick Aebischer, a foundingscientist of the company, reported that Phase I trialsdemonstrated that its CereCRIB implant for severe chronic painwas performed safely in three cancer patients.

The trial results were reported at the Eighth World Congress onPain in Paris. CytoTherapeutics (NASDAQ:CYTO) of Providence,R.I., said the study is designed to determine the safety of theimplant procedure, as well as the 30-day survival ofencapsulated, non-human (xenogeneic) cells that have beentransplanted into patients with intractable pain.

Implants retrieved from two of the trial patients after a periodof up to 60 days showed viable cells within the capsule, thecompany said. Two of the patients reported pain relief,including a reduction in narcotic usage, during the study.

The company said it expects complete results from the trial tobe available by the end of the year.

(c) 1997 American Health Consultants. All rights reserved.